Modelling the intestine-liver axis: The role of FXR agonists in a multi-organ microphysiological system model of non-alcoholic fatty liver disease
Here, we demonstrate the potential of a liver and a gut/liver microphysiological systems (MPS) to recapitulate NAFLD and NASH phenotypes in vitro and explore the molecular mechanisms underlying the development of NAFLD/NASH as well as assess the efficacy of novel therapeutic strategies.
The Human Touch
Webinar Series 5 Episode 4
In this webinar, we highlight how the liver-on-a-chip system can be used to assess the impact of HSD17B13 inhibitors on fibrosis, human metabolism and lipid droplets.
The Dash for NASH
Webinar Series 5 Episode 3
Find out how to: rapidly adopt an organ-on-a-chip (OOC) approach to NASH research, generate clinically translatable data from an industry-proven in vitro NASH model, and how OOC can help you unlock NASH disease mechanisms, and confirm drug efficacy and safety.
Microphysiological system for studying fatty liver disease and its impact on drug-induced liver injury
Kostrzewski et al
As a result of the increased prevalence of diabetes, obesity, and metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in developed countries. Using better in vitro models to fast-track therapeutic development but also accurately assess DILI risk in NASH patients ahead of the clinic is critical. Here, we show the potential of an in vitro 3D NASH model to accurately identify any DILI-associated risks.
Pros and cons of preclinical models of Non-Alcoholic Steatohepatitis
This infographic was made by Biotechniques to help educate people on our NASH-in-a-box kit and how it sets a new standard in the search for an approved NASH therapeutic.
Videos and animations
In Focus: Modeling NASH disease – organ-on-a-chip technologies
This short animation describes how our NASH-in-a-box kit enhances your chance of successfully developing NASH therapeutics by recreating our industry-proven NASH model in your laboratory. Created by Biotechniques.
Organ-on-a-Chip Models of Fatty Liver Disease
15-Minute Tech Blast – In this podcast developed by Biotechniques, our Lead Scientist Gareth Guenigault discussed NAFLD & NASH and their growing prevalence both in terms of cases and economic factors.
New Model Will Support Drug Discovery for Liver Disease NASH
Dr Audrey Doubourg discusses the therapeutic challenges of NASH and how our NASH-in-a-box kit will help to advance drug discovery.
This article is taken from Technology Networks, April 2022.
A pressing Need for Accurate Preclinical Models of Metabolic Disease
How using organ-on-a-chip (OOC) can more accurately recapitulate the physiology and functions of the human body by culturing under flow perfusion – to mimic the blood – in 3D.
This article is taken from European Biopharmaceutical Review January 2022, pages 28-31.
β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development
Rao et al., 2021
This study shows the effect of the presence of β2-spectrin (SPTBN1) in the promotion of sterol regulatory element (SRE)–binding protein (SREBP)–stimulated lipogenesis. These findings suggest SPTBN1 could be a potential target for a therapeutic against NASH and liver cancer.
Hype or hope – microphysiological systems?
This article in DDW examines MPS (microphysiological systems/organ-on-a-chip) in drug discovery and their place in the preclinical ‘toolbox’.
This article is taken from Drug Discovery World, October 2021.
Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system
Kostrzewski et al., 2021
It was shown in this study that the MPS NASH model, composed of a primary cell co-culture in various conditions, is able to model different characteristics of clinical NASH, including advanced disease with a quantifiable fibrosis phenotype as well as pharmaceutical intervention.